Caribou Biosciences (CRBU) Competitors $1.96 -0.03 (-1.51%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRBU vs. SOPH, FATE, VXRT, CLLS, PSTX, AVXL, CRMD, TRDA, ABUS, and DNTHShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include SOPHiA GENETICS (SOPH), Fate Therapeutics (FATE), Vaxart (VXRT), Cellectis (CLLS), Poseida Therapeutics (PSTX), Anavex Life Sciences (AVXL), CorMedix (CRMD), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. SOPHiA GENETICS Fate Therapeutics Vaxart Cellectis Poseida Therapeutics Anavex Life Sciences CorMedix Entrada Therapeutics Arbutus Biopharma Dianthus Therapeutics SOPHiA GENETICS (NASDAQ:SOPH) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Does the MarketBeat Community believe in SOPH or CRBU? Caribou Biosciences received 5 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.00% of users gave SOPHiA GENETICS an outperform vote while only 58.97% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1872.00% Underperform Votes728.00% Caribou BiosciencesOutperform Votes2358.97% Underperform Votes1641.03% Do analysts recommend SOPH or CRBU? SOPHiA GENETICS presently has a consensus price target of $6.50, suggesting a potential upside of 105.05%. Caribou Biosciences has a consensus price target of $11.25, suggesting a potential upside of 473.98%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, SOPH or CRBU? SOPHiA GENETICS has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Is SOPH or CRBU more profitable? SOPHiA GENETICS has a net margin of -110.71% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% Caribou Biosciences -1,290.81%-45.46%-38.07% Do institutionals & insiders believe in SOPH or CRBU? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor SOPH or CRBU? In the previous week, Caribou Biosciences had 4 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Caribou Biosciences and 2 mentions for SOPHiA GENETICS. Caribou Biosciences' average media sentiment score of 0.45 beat SOPHiA GENETICS's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, SOPH or CRBU? SOPHiA GENETICS has higher revenue and earnings than Caribou Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$62.37M3.32-$78.98M-$1.09-2.91Caribou Biosciences$34.48M5.15-$102.07M-$1.65-1.19 SummaryCaribou Biosciences beats SOPHiA GENETICS on 12 of the 17 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.20M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-1.1915.0083.5712.93Price / Sales5.15280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book0.634.696.936.25Net Income-$102.07M-$41.63M$119.12M$225.93M7 Day Performance-6.22%-4.73%-1.83%-1.32%1 Month Performance-0.51%-6.53%-3.64%0.60%1 Year Performance-63.02%25.63%31.64%26.23% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.9283 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$180.20M$34.48M-1.19100SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M0.00520FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeVXRTVaxart2.1372 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M-1.48109Analyst RevisionNews CoverageCLLSCellectis2.4726 of 5 stars$1.91-2.6%$7.00+266.5%-38.4%$108.94M$9.19M0.00290Analyst ForecastPSTXPoseida Therapeutics4.0406 of 5 stars$2.72-1.8%$15.00+451.5%-0.5%$269.98M$64.70M0.00260AVXLAnavex Life Sciences3.7023 of 5 stars$8.48+2.8%$40.00+372.0%+21.1%$698.72MN/A0.0040Upcoming EarningsCRMDCorMedix2.6748 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$671.70M$60,000.00-13.2630Insider TradeTRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$664.95M$129.01M11.28110ABUSArbutus Biopharma2.7999 of 5 stars$3.44-1.4%$5.50+59.9%+87.0%$661.33M$18.14M-8.0073Analyst ForecastDNTHDianthus Therapeutics1.5021 of 5 stars$20.77-6.7%$46.43+123.5%+78.7%$659.12M$2.83M0.0080 Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Fate Therapeutics Competitors Vaxart Competitors Cellectis Competitors Poseida Therapeutics Competitors Anavex Life Sciences Competitors CorMedix Competitors Entrada Therapeutics Competitors Arbutus Biopharma Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRBU) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBU Stock Alerts